Atlas Trials

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Clinical trial NCT05092958 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05092958
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Advanced Bladder Urothelial CarcinomaAdvanced Renal Pelvis Urothelial CarcinomaAdvanced Ureter Urothelial CarcinomaAdvanced Urethral Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaStage III Bladder Cancer AJCC v8Stage III Renal Pelvis and Ureter Cancer AJCC v8Stage III Renal Pelvis Cancer AJCC v8Stage III Ureter Cancer AJCC v8
Start date
2022-06-03
Primary completion
2029-07-15
Enrollment
654

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.